Steven Gillis - Pulmatrix Director

PULM Stock  USD 1.75  0.13  8.02%   

Director

Dr. Steven H. Gillis Ph.D., is Independent Director of the Company. Dr. Gillis was previously a director of Pulmatrix Operating from October 2009 until the date of the Merger. Since 2005, Dr. Gillis was a Managing Director at ARCH Venture Partners, a VC firm. From 1994 to 2005, Dr. Gillis served as Chief Executive Officer and chairman of the board of directors of Corixa Corporationrationration, which he cofounded in October 1994. Previously, Dr. Gillis served as a director, head of research and development, chief scientific officer and acting chief executive officer of Immunex Corporationrationration, which he cofounded. As a former director and chairman of Trubion Pharmaceuticals, Inc., Dr. Gillis led its acquisition by Emergent BioSolutions in the fall of 2010. Dr. Gillis currently serves as a director of Shire plc, Accelerator Corporationrationration, Oncofactor Corporationration and VBI Vaccines and serves as director and chairman of VentiRX Pharmaceuticals, Inc., Theraclone Sciences, Inc., Lycera Corporationration, Faraday Pharmaceuticals, Inc., Homology Medicines, Inc. and PhaseRx, Inc since 2015.
Age 65
Tenure 9 years
Address 99 Hayden Avenue, Lexington, MA, United States, 02421
Phone781 357 2333
Webhttps://www.pulmatrix.com

Latest Insider Transactions

2015-06-16Acquired 72750 shares @ 6.88View
Gillis received his B.A. in Biology and English from Williams College and his Ph.D. in Biological Science from Dartmouth College. We believe that Dr. Gillis’s experience in the VC industry, particularly with biotechnology and pharmaceutical companies, qualifies him to serve as a member of the Board.

Steven Gillis Latest Insider Activity

Tracking and analyzing the buying and selling activities of Steven Gillis against Pulmatrix stock is an integral part of due diligence when investing in Pulmatrix. Steven Gillis insider activity provides valuable insight into whether Pulmatrix is net buyers or sellers over its current business cycle. Note, Pulmatrix insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pulmatrix'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Pulmatrix Management Efficiency

The company has return on total asset (ROA) of (0.2529) % which means that it has lost $0.2529 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5918) %, meaning that it created substantial loss on money invested by shareholders. Pulmatrix's management efficiency ratios could be used to measure how well Pulmatrix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to drop to -0.5. In addition to that, Return On Assets is likely to drop to -0.43. At this time, Pulmatrix's Other Current Assets are very stable compared to the past year. As of the 28th of March 2024, Net Tangible Assets is likely to grow to about 37.6 M, while Non Current Assets Total are likely to drop about 3.1 M.
The company currently holds 857 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Pulmatrix has a current ratio of 8.03, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Pulmatrix until it has trouble settling it off, either with new capital or with free cash flow. So, Pulmatrix's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pulmatrix sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pulmatrix to invest in growth at high rates of return. When we think about Pulmatrix's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Mala AnandAgilent Technologies
53
David MilliganMadrigal Pharmaceuticals
77
Charles McDermottEquillium
45
Americo Romano23Andme Holding Co
58
Willard DereSeres Therapeutics
64
Heidi KunzAgilent Technologies
66
George ScangosAgilent Technologies
72
Staffan Gavel23Andme Holding Co
67
Helena Herlogsson23Andme Holding Co
N/A
Meryl ZausnerSeres Therapeutics
61
Werner CautreelsSeres Therapeutics
N/A
Bala ManianEquillium
72
Mark PruzanskiEquillium
50
Daniel PodolskyAgilent Technologies
67
Richard KenderSeres Therapeutics
62
Bruce KovnerMadrigal Pharmaceuticals
69
Kenneth BateMadrigal Pharmaceuticals
67
David BerrySeres Therapeutics
37
Richard LevyMadrigal Pharmaceuticals
60
Lorence KimSeres Therapeutics
43
Giuseppe Lettieri23Andme Holding Co
33
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people. Pulmatrix (PULM) is traded on NASDAQ Exchange in USA. It is located in 99 Hayden Avenue, Lexington, MA, United States, 02421 and employs 28 people. Pulmatrix is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Pulmatrix Leadership Team

Elected by the shareholders, the Pulmatrix's board of directors comprises two types of representatives: Pulmatrix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pulmatrix. The board's role is to monitor Pulmatrix's management team and ensure that shareholders' interests are well served. Pulmatrix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pulmatrix's outside directors are responsible for providing unbiased perspectives on the board's policies.
MBA CMA, Interim Officer
Terrance McGuire, Director
Matthew Sherman, Director
David Hava, Chief Scientific Officer
Alexander Klibanov, Founder
Akihisa Akao, Director
James Roach, Chief Medical Officer
Michael Higgins, Director
Steven Gillis, Director
Jean Sung, Vice President - Pharmaceutical Development
William Duke, CFO, Principal Financial Officer & Principal Accounting Officer
Robert Clarke, CEO and President and Director
Scott Rocklage, Director
Kurt Graves, Director
Richard Conley, Independent Director
Mark Iwicki, Chairman of the Board
Amit Munshi, Director
Gregory French, Independent Director
Margaret MD, Chief Officer
Ted Raad, CEO, Director
David JD, Advisor
Aidan Curran, VP Affairs
Teofilo MBA, CEO President
Teofilo Raad, CEO, Director

Pulmatrix Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pulmatrix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pulmatrix using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Pulmatrix is a strong investment it is important to analyze Pulmatrix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmatrix's future performance. For an informed investment choice regarding Pulmatrix Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Pulmatrix Stock analysis

When running Pulmatrix's price analysis, check to measure Pulmatrix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulmatrix is operating at the current time. Most of Pulmatrix's value examination focuses on studying past and present price action to predict the probability of Pulmatrix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulmatrix's price. Additionally, you may evaluate how the addition of Pulmatrix to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
CEOs Directory
Screen CEOs from public companies around the world
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Commodity Directory
Find actively traded commodities issued by global exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Global Correlations
Find global opportunities by holding instruments from different markets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Money Managers
Screen money managers from public funds and ETFs managed around the world
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Is Pulmatrix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.44)
Revenue Per Share
1.865
Quarterly Revenue Growth
(0.06)
Return On Assets
(0.25)
Return On Equity
(0.59)
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.